Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02720536
Other study ID # CICL670AIC04
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 16, 2016
Est. completion date July 23, 2019

Study information

Verified date February 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Extend evaluation of deferasirox film-coated tablet (FCT) formulation


Description:

Collection of additional safety and efficacy data with deferasirox film-coated tablet (FCT) in patients who had completed study CICL670F2201

- Provide patients who completed 24 weeks of treatment in the core study, CICL670F2201, the possibility to have additional treatment with the deferasirox FCT.

- Collect additional longer term data on the safety and the tolerability of the deferasirox FCT.

- Collect efficacy data on the deferasirox FCT in reduction or maintenance of iron burden as measured by serum ferritin level.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date July 23, 2019
Est. primary completion date July 23, 2019
Accepts healthy volunteers No
Gender All
Age group 10 Years and older
Eligibility Key Inclusion Criteria for subjects:

- Completed 24-weeks of study treatment as described in the core protocol (CICL670F2201).

- Were deemed to have tolerated deferasirox treatment by the investigator.

- Provided written informed consent/assent before any study-specific procedures were performed. For pediatric patients, consent was obtained from parent(s) or legal patient's representative. Investigators were to have also obtained assent of patients according to local, regional or national guidelines.

Key Exclusion for subjects:

The exclusion criteria followed those described for the core protocol CICl670F2201, which were as follows:

- Creatinine clearance below the contraindication limit in the locally approved prescribing information.

- Serum creatinine > 1.5 × upper limit of normal range (ULN) at Screening

- Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) > 5 × ULN,

- Significant proteinuria

- Patients with significant impaired gastrointestinal function or gastrointestinal disease

- Clinical or laboratory evidence of active Hepatitis B or Hepatitis C

- Patients with psychiatric or addictive disorders

- Patients with a known history of HIV seropositivity (Elisa or Western blot).

- History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there was an evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.

- Patients with a history of hypersensitivity to any of the study drug or excipients.

- Patients with significant medical condition that could interfere with the ability to participate in this study

- Patients who were participating in another clinical trial or receiving an investigational drug.

- Patients using prohibited medication,

- Patients with liver disease with severity of Child-Pugh Class B or C.

- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using effective methods of contraception during dosing of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deferasirox
Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.

Locations

Country Name City State
Austria Novartis Investigative Site Vienna
Greece Novartis Investigative Site Goudi-Athens GR
Greece Novartis Investigative Site Patras
Greece Novartis Investigative Site Thessaloniki
Italy Novartis Investigative Site Cagliari ITA
Italy Novartis Investigative Site Catania CT
Italy Novartis Investigative Site Cona FE
Italy Novartis Investigative Site Genova GE
Italy Novartis Investigative Site Lecce LE
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Verona VR

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Greece,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overview of Number of Participants With Adverse Events Numbers represent counts of participants within the categories. An adverse event (AE) was defined as treatment emergent if its onset date is on or after (=) the first administration of study treatment within this study or events present prior to start of study treatment but increased in severity on or after (=) the first administration of study treatment within this study but not later than 30 days after the last study treatment in this study Baseline up to approximately 25 months
Primary Change From Baseline Red Blood Cells (RBC) (10^12 Cells/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline White Blood Cells (WBC) (10^9 Cells/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline Platelets (10^9 Cells/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline Serum Creatinine (Umol/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline Creatinine Clearance (mL/Min) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) (U/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Primary Change From Baseline Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) (U/L) at Month 6 and Month 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline Baseline, 6 and 12 months
Secondary Change From Baseline of Serum Ferritin Level (ug/L) at Month 6 and 12 The change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Change = Post - Baseline. A negative change from baseline is regarded as an improvement in this study Baseline, 6 and 12 months
Secondary Percentage Relative Change From Baseline of Serum Ferritin (%) at Month 6 and 12 The percentage relative change from baseline at each time point is calculated only for subjects with a value at baseline and the particular time point. Post = Post baseline, Percentage relative change = 100 × ([Post - Baseline] / Baseline). Percentage relative change is calculated for each patient individually and then overall descriptive summary statistics is obtained for subjects with a value at baseline and the particular time point. A negative percentage relative change from baseline is regarded as an improvement in this study Baseline, 6 and 12 months
See also
  Status Clinical Trial Phase
Completed NCT05440487 - Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
Completed NCT01825512 - Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients Phase 3
Completed NCT06215287 - Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Completed NCT01740713 - Pharmacokinetic Study of Deferiprone in Paediatric Patients Phase 2